{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"No. of patients with worst-grade toxicity of 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"No. of patients with worst-grade toxicity of 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"No. of patients with worst-grade toxicity of 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"No. of patients with worst-grade toxicity of 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"No. of patients with worst-grade toxicity of 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Number of patients with worst-grade toxicity response of each grade (grade 1 to 5) following NCI Common Toxicity Criteria, with grade 1=mild adverse event; 2=moderate adverse event; 3=severe and undesirable adverse event; 4=life-threatening or disabling adverse event; 5=death","groups":[{"description":"Cisplatin, Starting dose 30 mg/m2 Dose level -1 20 mg/m2; Irinotecan, Starting Dose 50 mg/m2, Dose level -1 40 mg/m2","id":"OG000","title":"Therapeutic Intervention"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 weeks after last chemotherapy","title":"Number of Patients With Each Worst-grade Toxicity","type":"SECONDARY","unitOfMeasure":"participants"}